IDO1 and gastrointestinal stromal tumor: In GIST, imatinib has been reported to reduce intratumoral expression of the immunosuppressive enzyme IDO and to alter T-cell profiles by increasing the CD8+/Treg ratio, thereby reshaping the immune milieu.